Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07372430

Proximal Versus Distal Superior Cluneal Nerve Block in Entrapment Neuropathy

Superior cluneal nerve (SCN) entrapment is an underdiagnosed cause of chronic low back and gluteal pain. Although diagnostic nerve block is considered the gold standard for confirming SCN entrapment, there is no consensus regarding the optimal injection approach. This prospective observational study aims to compare the clinical effectiveness of proximal and distal ultrasound-guided SCN block techniques in patients diagnosed with SCN entrapment. Pain intensity and functional outcomes will be evaluated over the follow-up period to assess differences between the two approaches.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Health Sciences University Gaziosmanpaşa Physical Medicine and Rehabilitation Training and Research Hospita

Istanbul, 34255, Turkey (Türkiye)

Location status: Recruiting

Location contact

Tugba Bayraktar Celebioglu, MD

CONTACT

[email protected]

+905444720367

Tugce Yavuz Mollavelioglu, MD

CONTACT

[email protected]

+905056751666

About this study

The primary objective of this study is to compare the effects of two different ultrasound-guided injection techniques on pain intensity, functional status, neuropathic pain components, and quality of life in patients with suspected superior cluneal nerve (SCN) entrapment. Pain severity will be assessed using the Visual Analog Scale (VAS), functional status using the Oswestry Disability Index (ODI), neuropathic pain components using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), and quality of life using the Short Form-12 (SF-12). The study aims to determine which injection technique provides superior clinical outcomes.

The secondary objective is to evaluate lumbosacral angle, lumbar lordosis angle, pelvic tilt, sacral tilt, and the presence of scoliosis, and to investigate the relationship between these postural and radiological parameters, SCN entrapment, and treatment response.

Through this study, ultrasound-guided injection techniques used in the diagnosis and treatment of SCN entrapment will be comparatively evaluated, addressing an important gap in the current literature and providing high-level scientific evidence to guide clinicians in the management of chronic low back and gluteal pain.

This study is designed as a prospective, randomized, single-blind clinical study comparing two different ultrasound-guided injection techniques in patients with suspected superior cluneal nerve entrapment. The study population will consist of patients presenting to the Algology Outpatient Clinic of Health Sciences University Gaziosmanpaşa Physical Medicine and Rehabilitation Training and Research Hospital during the study period, who meet the inclusion and exclusion criteria, have chronic low back and/or gluteal pain, are suspected of having SCN entrapment based on clinical examination, have not benefited from conservative treatment, and voluntarily agree to participate in the study.

Based on a power analysis with 95% power, a total of 54 patients are planned to be included in the study, with 27 patients allocated to each group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age between 18 and 75 years
  • Chronic low back and/or gluteal pain lasting longer than 3 months
  • Localized point tenderness and/or paresthesia on palpation over the unilateral posterior iliac crest
  • Clinical suspicion of superior cluneal nerve entrapment based on physical examination
  • Failure to respond to conservative treatment
  • Ability and willingness to provide written informed consent

Exclusion criteria

  • Active local or systemic infection
  • Cognitive impairment or psychiatric disorders interfering with study participation
  • History of malignancy or cancer-related pain
  • Uncontrolled diabetes mellitus or severe comorbid conditions adversely affecting general health
  • Pregnancy
  • Known allergy to the medications used in the injection
  • Prominent radicular pain associated with neurological deficit
  • History of interventional procedures applied to the lumbar region within the last 6 months
  • Initiation of another lumbar interventional or medical treatment during the follow-up period
  • Suspected bilateral superior cluneal nerve entrapment
  • Sphincter dysfunction related to neurological disease
  • Bleeding diathesis or coagulation disorders

Treatment and study plan

Ultrasound-guided distal superior cluneal nerve injection

Procedure

The ultrasound probe will be placed over the posterior superior iliac crest to visualize the fibro-osseous tunnel where the superior cluneal nerve passes. Using an in-plane approach, the needle will be advanced toward the target area, and the injection will be administered at the fascial exit point of the nerve. A total injectate volume of 5 cc (2 cc bupivacaine, 2 cc dexamethasone, and 1 cc normal saline) will be administered. All procedures will be performed in the prone position under standard aseptic conditions.

Ultrasound-guided proximal superior cluneal nerve injection

Procedure

Patients randomized to the proximal injection group will undergo ultrasound-guided injection above the iliac crest level. The target will be the plane beneath the posterior layer of the thoracolumbar fascia. Using an in-plane approach, the injectate will be delivered into the interfascial plane. A total injectate volume of 5 cc (2 cc bupivacaine, 2 cc dexamethasone, and 1 cc normal saline) will be administered under ultrasound guidance. Patient positioning and aseptic conditions will be identical to those used in the distal perineural injection group.

Primary outcomes

  1. Visual Analog Scale (VAS)

    Time frame: Baseline, 1 month, and 3 months

    Primary Outcome Measure Visual Analog Scale for Pain (VAS): Change in pain intensity assessed using the Visual Analog Scale (VAS).The VAS is a 10-cm horizontal scale ranging from 0 (no pain) to 10 (worst imaginable pain).Higher scores indicate greater pain intensity, and a reduction in VAS score represents clinical improvement.

Secondary outcomes

  1. Oswestry Disability Index (ODI)

    Time frame: Baseline, 1 month, and 3 months

    Oswestry Disability Index (ODI): Change in disability related to low back pain assessed using the Oswestry Disability Index (ODI).The validated and reliability-tested Turkish version of the ODI will be used in this study.The ODI consists of 10 items, each scored from 0 to 5, yielding a maximum total raw score of 50.The total score is converted to a percentage using the following formula:ODI percentage = (Total score / 50) × 100

    Higher percentage scores indicate greater disability. Disability levels are interpreted as follows:

    • 0-20%: Minimal disability
    • 21-40%: Moderate disability
    • 41-60%: Severe disability
    • 61-80%: Crippling disability
    • 81-100%: Bed-bound or exaggerated symptoms

    A decrease in ODI percentage score indicates improvement in functional status.

  2. Leeds Assessment of Neuropathic Symptoms and Signs (LANSS)

    Time frame: Baseline, 1 month, and 3 months

    Assessment of neuropathic pain features using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) questionnaire.The LANSS scale consists of 7 items with a total score ranging from 0 to 24.A score of ≥12 indicates the presence of neuropathic pain mechanisms.Higher scores reflect greater neuropathic pain components.

  3. Short Form-12 Health Survey (SF-12)

    Time frame: Baseline, 1 month, and 3 months

    Health-related quality of life assessed using the Short Form-12 Health Survey (SF-12).The SF-12 generates two composite scores:

    • Physical Component Summary (PCS)
    • Mental Component Summary (MCS) Both PCS and MCS scores are calculated according to standard scoring algorithms.Higher scores indicate better physical and mental health-related quality of life, respectively.In this study, PCS and MCS scores will be analyzed separately to evaluate physical and mental aspects of quality of life.
  4. Baseline Postural and Radiological Characteristics in Patients with Superior Cluneal Nerve Entrapment

    Time frame: Baseline (pre-intervention)

    Baseline postural and radiological characteristics will be assessed prior to intervention in patients with superior cluneal nerve entrapment. Previously obtained standing lateral lumbosacral and pelvic radiographs will be used. Lumbar lordosis, sacral slope, lumbosacral angle, and pelvic tilt will be measured as radiographic angles in degrees on standing lateral images and categorized as decreased/normal/increased (lumbar lordosis, sacral slope, lumbosacral angle) or anterior/normal/posterior (pelvic tilt). Scoliosis will be evaluated based on physical examination and review of existing radiographs and MRI scans; when clinically indicated, standing scoliosis radiographs will be obtained. Scoliosis will be assessed using the Cobb method and recorded as present or absent. These findings will be descriptively reported.

Study contacts

Contact information is provided by the study sponsor or research team.

Tugce Yavuz Mollavelioglu, M.D

CONTACT

[email protected]

+905056751666

tugba bayraktar celebioglu, M.D

CONTACT

[email protected]

+905444720367

Sponsors and collaborators

Lead sponsor

Gaziosmanpasa Research and Education Hospital

Other Gov

Registry information

Official study title

Proximal Versus Distal Superior Cluneal Nerve Block in Superior Cluneal Nerve Entrapment: A Prospective, Randomized, Single-Blind Trial

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 28, 2026
Registry last updated
Jul 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.